Migraine

>

The NeurologyLive® Migraine Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with migraine disorders.

Latest News

Guillermo García Pérez de Sevilla, PhD (Credit: European University of Madrid)
Meta-Analysis Reveals Fatty Acid Supplementation Linked to Migraine Symptom Improvement

April 29th 2025

A recently published meta-analysis reported that fatty acid supplementation, particularly omega-3, may significantly reduce severity, duration, and frequency of migraine in patients.

Alex Jaimes, MD (Credit: X)
Switching Between Anti-CGRP Monoclonal Antibodies Reduces Headache Days in Nonresponders

April 24th 2025

Rajinder Bhardwaj, PhD (Credit: Certara)
Migraine Treatment Zavegepant Shows No Meaningful Impact on Oral Contraceptive Exposure

April 17th 2025

Lisette Kogelman, MSc (Credit: LinkedIn)
Large Danish Cohort Study Reveals No Significant Association Between HLA Alleles and Migraine

April 16th 2025

Andrew Blumenfeld, MD (Credit: BNL Health)
Post Hoc Analysis of ADVANCE Trial Reveals Atogepant Improves Functional Outcomes in Migraine

April 6th 2025

More News

NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and Optimization

NeuroVoices: Stephanie J. Nahas, MD, on Migraine Treatment Gaps and Optimization

Marco Meglio
May 19th 2021
Article

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Jason Sico, MD, MHS, FAHA, FAAN

Veterans Affairs Investigates gammaCore for Treatment of Post-Traumatic Headache

Victoria Johnson
May 17th 2021
Article

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Marco Meglio
May 15th 2021
Article

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

Lawrence Severt, MD, PhD
May 4th 2021
Video

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

Atogepant’s Impact on Patient-Reported Outcomes: Lawrence Severt, MD, PhD

Atogepant’s Impact on Patient-Reported Outcomes: Lawrence Severt, MD, PhD

Marco Meglio
April 28th 2021
Video

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

<123
© 2025 MJH Life Sciences

All rights reserved.